Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment

Oncogene volume 36, pages 5695–5708 (2017)Cite this article

Subjects

Abstract

Despite the promising targeted and immune-based interventions in melanoma treatment, long-lasting responses are limited. Melanoma cells present an aberrant redox state that leads to the production of toxic aldehydes that must be converted into less reactive molecules. Targeting the detoxification machinery constitutes a novel therapeutic avenue for melanoma. Here, using 56 cell lines representing nine different tumor types, we demonstrate that melanoma cells exhibit a strong correlation between reactive oxygen species amounts and aldehyde dehydrogenase 1 (ALDH1) activity. We found that ALDH1A3 is upregulated by epigenetic mechanisms in melanoma cells compared with normal melanocytes. Furthermore, it is highly expressed in a large percentage of human nevi and melanomas during melanocyte transformation, which is consistent with the data from the TCGA, CCLE and protein atlas databases. Melanoma treatment with the novel irreversible isoform-specific ALDH1 inhibitor [4-dimethylamino-4-methyl-pent-2-ynthioic acid-S methylester] di-methyl-ampal-thio-ester (DIMATE) or depletion of ALDH1A1 and/or ALDH1A3, promoted the accumulation of apoptogenic aldehydes leading to apoptosis and tumor growth inhibition in immunocompetent, immunosuppressed and patient-derived xenograft mouse models. Interestingly, DIMATE also targeted the slow cycling label-retaining tumor cell population containing the tumorigenic and chemoresistant cells. Our findings suggest that aldehyde detoxification is relevant metabolic mechanism in melanoma cells, which can be used as a novel approach for melanoma treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66: 271–289.

    Article  Google Scholar 

  2. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013; 24: 1697–1703.

    Article  CAS  Google Scholar 

  3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.

    Article  CAS  Google Scholar 

  4. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707–714.

    Article  CAS  Google Scholar 

  5. Vasiliou V, Pappa A, Petersen DR . Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact 2000; 129: 1–19.

    Article  CAS  Google Scholar 

  6. Vasiliou V, Nebert DW . Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics 2005; 2: 138–143.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Yoshida A, Hsu LC, Dave V . Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 1992; 46: 239–244.

    Article  CAS  Google Scholar 

  8. Blackwell LF, Bennett AF, Buckley PD . Relationship between the mechanisms of the esterase and dehydrogenase activities of the cytoplasmic aldehyde dehydrogenase from sheep liver. An alternative view. Biochemistry 1983; 22: 3784–3791.

    Article  CAS  Google Scholar 

  9. Chen Y, Mehta G, Vasiliou V . Antioxidant defenses in the ocular surface. Ocul Surf 2009; 7: 176–185.

    Article  Google Scholar 

  10. Estey T, Cantore M, Weston PA, Carpenter JF, Petrash JM, Vasiliou V . Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1. J Biol Chem 2007; 282: 4382–4392.

    Article  CAS  Google Scholar 

  11. Marchitti SA, Brocker C, Stagos D, Vasiliou V . Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008; 4: 697–720.

    Article  CAS  Google Scholar 

  12. Marcato P, Dean CA, Giacomantonio CA, Lee PW . Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011; 10: 1378–1384.

    Article  CAS  Google Scholar 

  13. Cheung AM, Wan TS, Leung JC, Chan LY, Huang H, Kwong YL et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007; 21: 1423–1430.

    Article  CAS  Google Scholar 

  14. Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P et al. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res 2013; 73: 7290–7300.

    Article  CAS  Google Scholar 

  15. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008; 3: e2428.

    Article  Google Scholar 

  16. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009; 69: 3382–3389.

    Article  CAS  Google Scholar 

  17. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008; 6: 1146–1153.

    Article  CAS  Google Scholar 

  18. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010; 102: 340–351.

    Article  CAS  Google Scholar 

  19. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010; 70: 5163–5173.

    Article  CAS  Google Scholar 

  20. Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD et al. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 2012; 30: 2100–2113.

    Article  CAS  Google Scholar 

  21. Yue L, Huang ZM, Fong S, Leong S, Jakowatz JG, Charruyer-Reinwald A et al. Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. Melanoma Res 2015; 25: 138–148.

    Article  CAS  Google Scholar 

  22. Januchowski R, Wojtowicz K, Zabel M . The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother 2013; 67: 669–680.

    Article  CAS  Google Scholar 

  23. Alnouti Y, Klaassen CD . Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice. Toxicol Sci 2008; 101: 51–64.

    Article  CAS  Google Scholar 

  24. Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev 2012; 64: 520–539.

    Article  CAS  Google Scholar 

  25. Roch AM, Quash G, Michal Y, Chantepie J, Chantegrel B, Deshayes C et al. Altered methional homoeostasis is associated with decreased apoptosis in BAF3 bcl2 murine lymphoid cells. Biochem J 1996; 313 (Pt 3): 973–981.

    Article  CAS  Google Scholar 

  26. Quash G, Fournet G, Chantepie J, Gore J, Ardiet C, Ardail D et al. Novel competitive irreversible inhibitors of aldehyde dehydrogenase (ALDH1): restoration of chemosensitivity of L1210 cells overexpressing ALDH1 and induction of apoptosis in BAF(3) cells overexpressing bcl(2). Biochem Pharmacol 2002; 64: 1279–1292.

    Article  CAS  Google Scholar 

  27. Quash G, Fournet G, Courvoisier C, Martinez RM, Chantepie J, Paret MJ et al. Aldehyde dehydrogenase inhibitors: alpha,beta-acetylenic N-substituted aminothiolesters are reversible growth inhibitors of normal epithelial but irreversible apoptogens for cancer epithelial cells from human prostate in culture. Eur J Med Chem 2008; 43: 906–916.

    Article  CAS  Google Scholar 

  28. Monneuse O, Mestrallet JP, Quash G, Gilly FN, Glehen O . Intraperitoneal treatment with dimethylthioampal (DIMATE) combined with surgical debulking is effective for experimental peritoneal carcinomatosis in a rat model. J Gastrointest Surg 2005; 9: 769–774.

    Article  Google Scholar 

  29. Wittgen HG, van Kempen LC . Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res 2007; 17: 400–409.

    Article  CAS  Google Scholar 

  30. Esterbauer H, Eckl P, Ortner A . Possible mutagens derived from lipids and lipid precursors. Mutat Res 1990; 238: 223–233.

    Article  CAS  Google Scholar 

  31. Summerfield FW, Tappel AL . Cross-linking of DNA in liver and testes of rats fed 1,3-propanediol. Chem Biol Interact 1984; 50: 87–96.

    Article  CAS  Google Scholar 

  32. Townsend AJ, Leone-Kabler S, Haynes RL, Wu Y, Szweda L, Bunting KD . Selective protection by stably transfected human ALDH3A1 (but not human ALDH1A1) against toxicity of aliphatic aldehydes in V79 cells. Chem Biol Interact 2001; 130-132: 261–273.

    Article  CAS  Google Scholar 

  33. Hill BG, Bhatnagar A . Beyond reactive oxygen species: aldehydes as arbitrators of alarm and adaptation. Circ Res 2009; 105: 1044–1046.

    Article  CAS  Google Scholar 

  34. Grammatico P, Maresca V, Roccella F, Roccella M, Biondo L, Catricala C et al. Increased sensitivity to peroxidizing agents is correlated with an imbalance of antioxidants in normal melanocytes from melanoma patients. Exp Dermatol 1998; 7: 205–212.

    Article  CAS  Google Scholar 

  35. Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW et al. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics 2011; 5: 283–303.

    Article  CAS  Google Scholar 

  36. Venza M, Visalli M, Beninati C, De Gaetano GV, Teti D, Venza I . Cellular mechanisms of oxidative stress and action in melanoma. Oxid Med Cell Longev 2015; 2015: 481782.

    Article  Google Scholar 

  37. Tomita H, Tanaka K, Tanaka T, Hara A . Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 2016; 7: 11018–11032.

    Article  Google Scholar 

  38. Boonyaratanakornkit JB, Yue L, Strachan LR, Scalapino KJ, LeBoit PE, Lu Y et al. Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol 2010; 130: 2799–2808.

    Article  CAS  Google Scholar 

  39. Prasmickaite L, Engesaeter BO, Skrbo N, Hellenes T, Kristian A, Oliver NK et al. Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS ONE 2010; 5: e10731.

    Article  Google Scholar 

  40. Burger PE, Gupta R, Xiong X, Ontiveros CS, Salm SN, Moscatelli D et al. High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells 2009; 27: 2220–2228.

    Article  CAS  Google Scholar 

  41. Fournet G, Martin G, Quash G . alpha,beta-Acetylenic amino thiolester inhibitors of aldehyde dehydrogenases 1&3: suppressors of apoptogenic aldehyde oxidation and activators of apoptosis. Curr Med Chem 2013; 20: 527–533.

    CAS  PubMed  Google Scholar 

  42. Moore N, Lyle S . Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol 2011; 2011: 1–11.

    Article  Google Scholar 

  43. Moore N, Houghton J, Lyle S . Slow-cycling therapy-resistant cancer cells. Stem Cells Dev 2012; 21: 1822–1830.

    Article  CAS  Google Scholar 

  44. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ . Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593–598.

    Article  CAS  Google Scholar 

  45. Li X, Wan L, Geng J, Wu CL, Bai X . Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J Thorac Oncol 2012; 7: 1235–1245.

    Article  Google Scholar 

  46. Marcato P, Dean CA, Liu RZ, Coyle KM, Bydoun M, Wallace M et al. Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. Mol Oncol 2015; 9: 17–31.

    Article  CAS  Google Scholar 

  47. Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, Ostmark B et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer 2008; 7: 87.

    Article  Google Scholar 

  48. Dalleau S, Baradat M, Gueraud F, Huc L . Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. Cell Death Differ 2013; 20: 1615–1630.

    Article  CAS  Google Scholar 

  49. Sovic A, Borovic S, Loncaric I, Kreuzer T, Zarkovic K, Vukovic T et al. The carcinostatic and proapoptotic potential of 4-hydroxynonenal in HeLa cells is associated with its conjugation to cellular proteins. Anticancer Res 2001; 21: 1997–2004.

    CAS  PubMed  Google Scholar 

  50. Pizzimenti S, Barrera G, Dianzani MU, Brusselbach S . Inhibition of D1, D2, and A-cyclin expression in HL-60 cells by the lipid peroxydation product 4-hydroxynonenal. Free Radic Biol Med 1999; 26: 1578–1586.

    Article  CAS  Google Scholar 

  51. Wonisch W, Kohlwein SD, Schaur J, Tatzber F, Guttenberger H, Zarkovic N et al. Treatment of the budding yeast Saccharomyces cerevisiae with the lipid peroxidation product 4-HNE provokes a temporary cell cycle arrest in G1 phase. Free Radic Biol Med 1998; 25: 682–687.

    Article  CAS  Google Scholar 

  52. Barrera G, Di Mauro C, Muraca R, Ferrero D, Cavalli G, Fazio VM et al. Induction of differentiation in human HL-60 cells by 4-hydroxynonenal, a product of lipid peroxidation. Exp Cell Res 1991; 197: 148–152.

    Article  CAS  Google Scholar 

  53. Pizzimenti S, Laurora S, Briatore F, Ferretti C, Dianzani MU, Barrera G . Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation. Free Radic Biol Med 2002; 32: 233–245.

    Article  CAS  Google Scholar 

  54. Rodriguez-Torres M, Allan AL . Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors. Clin Exp Metastasis 2016; 33: 97–113.

    Article  CAS  Google Scholar 

  55. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S et al. Beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012; 18: 892–901.

    Article  CAS  Google Scholar 

  56. Andreu-Perez P, Hernandez-Losa J, Moline T, Gil R, Grueso J, Pujol A et al. Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth. BMC Cancer 2010; 10: 265.

    Article  Google Scholar 

  57. Lopez-Fauqued M, Gil R, Grueso J, Hernandez-Losa J, Pujol A, Moline T et al. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. Int J Cancer 2010; 126: 1549–1561.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Dr G Quash is gratefully acknowledged for critical reading of the manuscript and his contributions. We also thank Dr HG Palmer for his generous contribution. This work was supported by funds from Advanced BioDesign (MPA), the Spanish Health Ministry (Fondo de Investigaciones Sanitarias-FIS) PI1400375-Fondos FEDER, AECC-GCB15152978SOEN, Marie Curie Actions (IEF_METABOSET-627869) supported MPA.

Author information

Author notes

  1. S Sánchez-Redondo

    Present address: 10Current address: Microenvironment and Metastasis Group at CNIO, Madrid 28029, Spain.,

Authors and Affiliations

  1. Biomedical Research in Melanoma-Animal Models and Cancer Laboratory-Oncology Program, Vall d'Hebron Research institute VHIR-Vall d'Hebron Hospital, Barcelona-UAB, Spain

    M Pérez-Alea, K McGrail, S Sánchez-Redondo, B Ferrer, V Garcia-Patos & J A Recio

  2. Anatomy Pathology Department, Vall d’Hebron Hospital, Barcelona-UAB, Spain

    B Ferrer & J Hernandez-Losa

  3. Institut de Chimie et Biochimie Moléculaire et Supramoléculaire, UMR-CNRS 5246, Université de Lyon, Université Claude Bernard-Lyon1, Villeurbanne, France

    G Fournet

  4. Ramon y Cajal University Hospital, Madrid, Spain

    J Cortés

  5. Clinical Oncology Program, Vall d’Hebron Institute of Oncology-VHIO, Vall d’Hebron Hospital, Barcelona-UAB, Spain

    J Cortés & E Muñoz

  6. Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain

    S Tenbaum

  7. Advanced BioDesign, Parc Technologique de Lyon, Woodstock - Bâtiment Cèdre 1, Saint Priest, France

    G Martin & I Ceylan

  8. Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire La Conception, Marseille, France

    R Costello

  9. Dermatology Department, Vall d’Hebron Hospital, Barcelona-UAB, Spain

    V Garcia-Patos

Authors
  1. M Pérez-Alea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K McGrail
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Sánchez-Redondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Ferrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Fournet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Cortés
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Hernandez-Losa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Tenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R Costello
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. I Ceylan
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. V Garcia-Patos
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J A Recio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J A Recio.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pérez-Alea, M., McGrail, K., Sánchez-Redondo, S. et al. ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment. Oncogene 36, 5695–5708 (2017). https://doi.org/10.1038/onc.2017.160

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2017.160

This article is cited by

Search

Advanced search

Quick links